IMARA INC (IMRA)

Company Profile

Imara, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Brookline, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. The company is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The firm is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).

Company Info

IMARA INC

1309 Beacon Street, Suite 300

Brookline MASSACHUSETTS 02116

P: 16172062020.0

CEO: Rahul D. Ballal

Employees: 6

Website: https://imaratx.com/